HRMY

Harmony BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$40.00

+29.4% vs current

Most likely

Base case

45%

Probability

Target price

$33.00

+6.8% vs current

B-

Bear case

30%

Probability

Target price

$24.00

-22.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This remains a cautious post-earnings monitoring memo rather than a fresh bullish turn. Primary-source support improved materially because the May 7, 2026 earnings release and 8-K confirmed growth, guidance, liquidity, and pipeline timing, but analyst revision evidence was unavailable at T+1. Market reaction also looks muted rather than confirming a rerating: the May 7 anchor close was $31.42 and the latest checked price on May 8, 2026 was $31.02, about 1.3% lower. Combined with the deterministic prior still skewing negative, confidence should stay moderate at best.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQ1 print confirmed revenue growth and reiterated 2026 guide, but margins and EPS were pressured by licensing costsMedium impact

Harmony reported Q1 2026 WAKIX net revenue of $215.4 million, up 17% year over year, and reiterated 2026 net revenue guidance of $1.0 billion to $1.04 billion, while noting more pronounced Q1 market-access headwinds; net income fell to $32.5 million from $45.6 million as licensing agreements increased royalties and R&D expense [#8-K-2026-05-07].

2026-06-30eventPitolisant GR NDA timing is the clearest near-term franchise-extension milestoneHigh impact

Management said Pitolisant GR remains on track for NDA submission in Q2 2026 with an anticipated PDUFA date in Q1 2027, supporting the case that Harmony is trying to extend the pitolisant franchise beyond the current WAKIX base and into the 2040s through follow-on IP and formulation work [#8-K-2026-05-07].

2026-07-15eventMid-2026 BP-205 Phase 1 PK data is the next meaningful pipeline signal beyond WAKIXHigh impact

Harmony said BP-205 Phase 1 SAD/MAD work is ongoing in Europe, with clinical PK, safety, and tolerability data from the SAD phase expected in mid-2026 and a U.S. IND also planned for mid-2026; that creates a second-half franchise-diversification check, but it remains early-stage and should be treated cautiously [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology